key: cord-0261765-x7fveulw
authors: Staessen, J. A.; Wendt, R.; Yu, Y.-L.; Thijs, L.; Siwy, J.; Raad, J.; Metzger, J.; Neuhaus, B.; Papkalla, A.; von der Leyen, H.; Mebazaa, A.; Dudoignon, E.; Spasovski, G.; Milenkova, M.; Canevska-Taneska, A.; Psichogiou, M.; Rajzer, M. W.; Fulawka, L.; Dzitkowska-Zabielska, M.; Weiss, G.; Feldt, T.; Stegemann, M.; Normark, J.; Zoufaly, A.; Schmiedel, S.; Seilmaier, M.; Rumpf, B.; Banasik, M.; Krajewska, M.; Catanese, L.; Rupprecht, H.; Czerwienska, B.; Peters, B.; Nilsson, A.; Rothfuss, K.; Luebbert, C.; Mischak, H.; Beige, J.
title: Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a cohort study
date: 2022-01-23
journal: nan
DOI: 10.1101/2022.01.20.22269599
sha: c3a8ecdb02313701ca9fbe5792710a5ed656b2d8
doc_id: 261765
cord_uid: x7fveulw

Background The SARS CoV-2 pandemic remains a worldwide challenge. The CRIT Cov U pilot study generated a urinary proteomic biomarker consisting of 50 peptides (COV50), which predicted death and disease progression. Following the interim analysis demanded by the German government, the full dataset was analysed to consolidate findings and propose clinical applications. Methods In eight European countries, 1012 adults with PCR-confirmed COVID-19 were followed up for death and progression along the 8 point WHO scale. Capillary electrophoresis coupled with mass spectrometry was used for urinary proteomic profiling. Statistical methods included logistic regression, receiver operating curve analysis with comparison of the area under curve (AUC) between nested models. Hospitalisation costs were derived from the care facility corresponding with the Markov chain probability of reaching WHO scores ranging from 3 to 8 and flat-rate hospitalistion costs standardised across countries. Findings The entry WHO scores were 1-3, 4-5 and 6 in 445 (44,0%), 529 (52,3%), and 38 (3,8%) patients, of whom 119 died and 271 progressed. The standardised odds ratios associated with COV50 for death were 2,44 (95% CI, 2,05-2,92) unadjusted and 1,67 (1,34-2,07) if adjusted for sex, age, body mass index, comorbidities and baseline WHO score, and 1,79 (1,60-2,01) and 1,63 (1,40-1,90), respectively, for disease progression (p<0,0001 for all). The predictive accuracy of optimised COV50 thresholds were 74,4% (95% CI, 71,6-77,1) for mortality (threshold 0,47) and 67,4% (64,1-70,3) for disease progression (threshold 0,04). On top of covariables and the baseline WHO score, these thresholds improved AUCs from 0,835 to 0,853 (p=0,0331) and from 0,697 to 0,730 (p=0,0008) for death and progression, respectively. Of 196 ambulatory patients, 194 (99,0%) did not reach the 0,04 threshold. Earlier intervention guided by high-risk COV50 levels should reduce hospital days with cost reductions expressed per 1000 patient-days ranging from MEuro 1,208 (95% percentile interval, 1,035-1,406) at low risk (COV50 <0,04) to MEuro 4,503 (4,107-4,864) at high risk (COV50 above 0,04 and age above 65 years). Interpretation The urinary proteomic COV50 marker is accurate in predicting adverse COVID-19 outcomes. Even in mild-to-moderate PCR-confirmed infections (WHO scores 1-5), the 0,04 threshold justifies earlier drug treatment, thereby reducing hospitalisation days and costs.

Background The SARS-CoV-2 pandemic remains a worldwide challenge. The CRIT-Cov-U pilot study generated a urinary proteomic biomarker consisting of 50 peptides (COV50), which predicted death and disease progression. Following the interim analysis demanded by the German government, the full dataset was analysed to consolidate findings and propose clinical applications.

In eight European countries, 1012 adults with PCR-confirmed COVID-19 were followed up for death and progression along the 8-point WHO scale. Capillary electrophoresis coupled with mass spectrometry was used for urinary proteomic profiling.

Statistical methods included logistic regression, receiver operating curve analysis with comparison of the area under curve (AUC) between nested models. Hospitalisation costs were derived from the care facility corresponding with the Markov chain probability of reaching WHO scores ranging from 3 to 8 and flat-rate hospitalistion costs standardised across countries.

Findings The entry WHO scores were 1-3, 4-5 and 6 in 445 (44·0%), 529 (52·3%), and 38 (3·8%) patients, of whom 119 died and 271 progressed. The standardised odds ratios associated with COV50 for death were 2·44 (95% CI, 2·05-2·92) unadjusted and 1·67 (1·34-2·07) if adjusted for sex, age, body mass index, comorbidities and baseline WHO score, and 1·79 (1·60-2·01) and 1·63 (1·40-1·90), respectively, for disease progression (p<0·0001 for all). The predictive accuracy of optimised COV50 thresholds were 74·4% (95% CI, 71·6-77·1) for mortality (threshold 0·47) and 67·4% (64·1-70·3) for disease progression (threshold 0·04). On top of covariables and the baseline WHO score, these thresholds improved AUCs from 0·835 to 0·853 (p=0·0331) and from 0·697 to 0·730 (p=0·0008) for death and

The SARS-CoV-2 pandemic remains a challenge for health care worldwide. Globally, during the week of 15-21 November 2021, nearly 3·6 million new cases and over 51,000 deaths were reported, reflecting 6% increases in both metrics compared to the preceding week. 1 While the pandemic is stretching health care resources over what is sustainable in the long run, the world is now bracing for the Omicron variant with higher transmissibility and potentially more resistance against the immunological response to vaccines or previous infection. 2, 3 Until now COVID-19 patients were stratified for risk based on age, obesity, comorbidities and disease-severity scales.

An extensive literature search (appendix 2) did not reveal any predictive biomarker allowing to select high-risk COVID-19 patients for early treatment. Urinary proteomic profiling (UPP) generates classifiers representative for pathogenic molecular mechanisms, which in case of SARS-CoV-2 infection are generally independent of mutating virus strains and which may inform treatment, in particular with pharmacological agents not specifically directed against the variable S-protein domains of evolving SARS-CoV2 strains. Following a insistent request from the German government, an interim analysis of the Prospective Validation of a Proteomic Urine Test for Early and Accurate Prognosis of the Critical Complications in Patients with SARS-CoV-2 Infection Study (CRIT-Cov-U) described the discovery, replication and internal and external validation of COV50. This novel UPP biomarker consists of 50 deregulated urinary peptides (appendix 1 p 8) and predicts death and progression across the COVID-19 WHO stages over beyond risk factors and comorbidities. 4 The objectives of the current study were to consolidate the interim findings in the full study sample and to propose potential applications of the COV50 marker in clinical practice and trial design. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint CRIT-Cov-U was a prospective multicentre cohort study. 4 Eligible patients were nonanuric adults (≥18 years), capable to give written informed consent, with PCR-confirmed SARS-CoV-2 infection diagnosed in ambulatory care or on the first hospitalisation day. All patients meeting the eligibility criteria were enrolled without any exclusion in two phases: 228 patients were recruited from 25 March 2020 until 18 November 2020 and were included in the interim report; 4 recruitment of 784 patients continued from 30 April 2020 until 14 April 2021, so that the full study cohort comprised 1012 individuals. Five centres participated in the initial enrolment of patients and an additional 12 in the continued recruitment. Two sites were located in Austria (65 patients enrolled), one in France (49), seven in Germany (458), one in Greece (30), one in North Macedonia (137), four in Poland (149), one in Spain (23), and two in Sweden (101).

All patients were followed up until recovery, hospital discharge or death. On days 0-3, 4-7 and 10-21 after diagnosis surviving patients were staged according to the 8-point WHO Clinical Progression Scale. 5 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 23, 2022. ; https://doi.org/10.1101/2022.01.20.22269599 doi: medRxiv preprint COV50 as guide to earlier COVID-19 treatment -9spectrometry, peptide sequencing, and for evaluation, calibration and quality control of the mass spectrometric data are described in detail in appendix 1 (p 2-5).

The initial sample size calculations informed by a proof-of-concept study 6 required 212 patients with critical COVID-19 (WHO stage ≥6) to be contrasted with 271 patients with mild symptoms (WHO stage <4) to identify and validate a UPP biomarker having 75% sensitivity and 80% specificity. Given the 33% progression rate from mild to severe disease in the pilot study 6 and accounting for 15% of missing data, the sample size for the full study was set at 645 patients. Based on the interim study, 4 in which the mortality rate was 10·1% (23/228), the sample size for the full study was revised to 1000 patients.

For database management and statistical analysis, SAS software version 9·4 was used.

Significance was a 2-tailed significance of 0·05 or less. Means and proportions were compared using the large-sample z test or ANOVA and Fisher's exact test, respectively.

The predefined endpoints were mortality and progression across the 8-point WHO scale of disease severity. The 95% confidence intervals of rates were computed as R ± 1.96 × √(R/T), where R and T are the rate and the denominator used to calculate the rate. The risk of incident endpoints was related to the baseline COV50 level by logistic regression, unadjusted or adjusted for sex, age, the entry WHO scale and comorbidities including hypertension, heart failure, diabetes, and cancer. The differences in the COV50 odds ratios between initial and continued recruitment were tested by introduction of the interaction between study phase and baseline COV50 in the logistic models. Performance of COV50 in risk stratification was assessed by the area (AUC) under the receiver operating curve (ROC) and the Delong approach to compare the AUCs between nested models. The COV50 thresholds optimised by the Youden index were 0·47 for mortality and 0·04 for worsening WHO score. 4

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 23, 2022. ; https://doi.org/10.1101/2022.01.20.22269599 doi: medRxiv preprint COV50 as guide to earlier COVID-19 treatment -10-A Markov chain analysis was conducted using SAS IML and bootstrapped 1000 times to generate the transition probabilities from the entry to follow-up WHO scores (appendix 1 p 17). 7 The transition probabilities were computed for various risk strata defined by the entry 

The funder of the study had no role in the study design, data collection, data analysis, data interpretation, or the writing of the report. All authors had full access to all of the data in the study and had the final responsibility for the decision to submit the manuscript.

The 1012 participants making up the full dataset were on average 62·3 years old, included 447 (44·2%) women, 557 (55·0%) patients with hypertension, 154 (15·2%) with heart failure, 257 (25·4%) with diabetes, and 106 (10·5%) patients with cancer (appendix 1 p 18). The WHO score at enrolment (table 1) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 23, 2022. ; https://doi.org/10.1101/2022.01.20.22269599 doi: medRxiv preprint COV50 as guide to earlier COVID-19 treatment -11scored lower on the WHO scale (table 1; p<0·0001), included more patients with a history of cancer (5·7 vs 11·9%; p=0·0117), but fewer participants on inhibitors of the reninangiotensin system (53·5% vs 38·9%; p<0·0001). Otherwise, patients recruited initially and later had similar characteristics (table 1), in particular a comparable entry level of COV50 (-0·19 vs -0·24; p=0·5918). In the whole study population (appendix 1 p 11), the proportion of women and the mean values of diastolic blood pressure decreased across increasing fourths of the COV50 distribution, whereas age, heart rate and the rates of hypertension, heart failure, diabetes mellitus and cancer increased.

No patient was lossed to follow-up. Median (5th-95th percentile interval) follow-up was 10 days (1-34) for mortality (119 deaths) and 10 days (2-26) for worsening WHO score (271 cases). The baseline COV50 distribution shifted upward (p<0·0001), when plotted against the worst WHO score attained during follow-up (appendix 1 p 20). In the whole study population (table 2), the relative risk of death expressed per 1-SD increment in COV50 at entry was 2·44 (95% confidence interval, 2·05-2·92; p<0·0001) unadjusted and 1·67 (1·34-2·07) when fully adjusted for sex, age, body mass index, the presence of comorbidities, and the baseline WHO score; for progression in the WHO score (table 3) , the corresponding odds ratios were 1·79 (1·60-2·01) unadjusted and 1·63 (1·10-1·90) fully adjusted. In analyses dichotomised by study phase, the risk associated with COV50 was similar for both endpoints, irrespective of adjustment (table 2). The unadjusted odds ratios for initial compared with continued recruitment were 2·45 (1·69-3·54) vs 2·47 (2·02-3·03) for mortality (p=0·9605) and 1·95 (1·52-2·51) vs 1·77 (1·56-1·73) for worsening WHO score (p=0·5150).

The corresponding fully adjusted estimates (table 2) were 2·27 (1·34-3·83) vs 1·55 (1·21-1·98) for mortality (p=0·9380) and 1·95 (1·52-2·51) vs 1·77 (1·56-1·73) for worsening WHO score (p=0·1645). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 23, 2022. ; https://doi.org/10.1101/2022.01.20.22269599 doi: medRxiv preprint COV50 as guide to earlier COVID-19 treatment -12-In the whole study population, the AUC of the continuously distributed COV50 urinary marker was 0·81 (95% confidence interval, 0·77-0·85) for mortality and 0·72 (0·62-0·75) for worsening WHO score ( (table 3) . For both endpoints, these estimates were consistent in the early and continued recruitment phases (table 3) .

The odds ratios and discriminatory performance of single baseline risk factors are summarised by recruitment phase in appendix 1 p 12. In the whole study population, on top of sex, age, body mass index, comorbidities, and the baseline WHO score, COV50 analysed as continuously distributed variable and per threshold significantly improved the AUC (figure 1). For mortality, application of the continuously distributed COV50 marker and the 0·47 COV50 threshold, resulted in an increase of the AUC from 0·835 to 0·854 (p=0·0221) and from 0·835 to 0·853 (p=0·0331); for worsening WHO score, the AUC increased from 0·697 to 0·740 (p=0·0001) for the continuously distributed marker and from 0·697 to 0·730 (p=0·0008) for the 0·04 threshold. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 23, 2022. in the highest risk stratum (COV50 ≥0·04 and age ≥65 years).

COV50 is a novel urinary biomarker, consisting of 50 deregulated urinary peptides (appendix 1 pp 8-10). COV50 predicts death and disease progression over and beyond clinical risk factors, comorbidities and the WHO score at presentation. COV50 analysed as single continuously distributed risk factor generated AUCs for mortality and disease progression substantially greater than a 10-year age increment or 1-point increase in the baseline WHO score (appendix 1 p 12). The optimised COV50 thresholds had 74·4% predictive accuracy for mortality and 67·4% for disease progression (table 3) . Both COV50 thresholds and COV50 as continuously distributed variable significantly improved the AUC (figure 1).

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 23, 2022. ; https://doi.org/10.1101/2022.01.20.22269599 doi: medRxiv preprint COV50 as guide to earlier COVID-19 treatment -14-COV50 is easily administrable, non-invasive, relatively inexpensive balanced against hospitalisation costs, and has high positive and low negative likelihood ratios (table 3) .

COV50 is registered in Germany and available for clinical and research purposes throughout the European Union. The UPP does not change when urine is stored for 5 days at room temperature in borated test tubes, 9 thereby providing a wide time window for sample handling, thereby enabling remote testing in non-hospitalised patients with PCR-confirmed COVID-19 infection. UPP profiling requires one day from receipt at the laboratory facility, currently in Hannover, Germany. 9 Furthermore, for research purposes urine can be indefinitely stored at -20 °C without UPP alteration. 9 The COV50 test is predictive at the initial stage of infection, when progression to critical illness is still uncertain. Thus, a highrisk test outcome can move patients across the action threshold, allowing the early administration of effective treatments, either in ambulatory or hospitalised care. An extensive literature review (appendix 2) identified effective treatment modalities that might be administered earlier in response to a high-risk UPP risk profile. Such treatments include systemic 10 or inhaled 11 corticosteroids, antiviral agents administered as single agents 12 or cocktails, 13 monoclonal antibodies antagonising the interleukin-6-receptor 14,15 or directed against the viral spike protein, 16,17 or a selective σ1-receptor agonist. 18 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 23, 2022. ; https://doi.org/10.1101/2022.01.20.22269599 doi: medRxiv preprint COV50 as guide to earlier COVID-19 treatment -15associated with life-threatening COVID-19. 21 Another hallmark of the COV50 UPP is the reduction in urinary peptides derived from CD99. 22 This observation reflects the loss of endothelial integrity, interference with transendothelial migration of monocytes, neutrophils and T-cells, 22 and damage of the endothelial tight junctions. The resulting exposure of collagen to the circulating blood triggers the thrombotic complications specific for COVID-19. 23 As also observed in chronic obstructive lung disease, 24 with increasing COVID-19 severity, the UPP reveals downregulation of the polymeric immunoglobulin receptor, 22 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 23, 2022. ; https://doi.org/10.1101/2022.01.20.22269599 doi: medRxiv preprint COV50 as guide to earlier COVID-19 treatment -16over later treatment guided by clinical deterioration, presumably applying the test will not impact on drug costs.

Although COVID-19 affects the heart and kidney, COV50 shares only one urinary peptide with HF1, 13 with CKD273 and two with both classifiers (appendix 1 p 21), which are disease-specific classifiers respectively predictive of left ventricle dysfunction 29 or chronic kidney disease or diabetic nephropathy. 30 Thus, COV50 is highly specific for the molecular pathogenic mechanisms associated with SARS-CoV-2 infection. In addition, the high consistency in the discriminatory performance of COV50 among patients recruited initially and later (tables 2 and 3) represents a replication within the CRIT-Cov-U cohort. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 23, 2022. 

The study protocol is available at the German Register for Clinical Studies (www.drks.de), number DRKS00022495. Anonymised participants data will be made available upon request directed to the corresponding author. Proposals will be reviewed and approved by the funder, investigators and collaborators based on scientific merit. After approval of a proposal, data can be shared through a secure online platform after signing a data access and confidentiality agreement. Data will be made available for a minimum of 3 years after a request has been received and approved.

HM is the co-founder and co-owner of Mosaiques-Diagnostics GmbH, JS and JR are employees of Mosaiques-Diagnostics GmbH, Hannover, Germany. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 23, 2022. 

This study is the first to include a COVID-19-specific biomarker to guide early intervention. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 23, 2022. ; https://doi.org/10.1101/2022.01.20.22269599 doi: medRxiv preprint COV50 as guide to earlier COVID-19 treatment -19-WHO score, the continuously distributed urinary marker and its optimised thresholds improved the AUCs from 0·835 to 0·854 and to 0·853 for death and from 0·697 to 0·740 and to 0·730 for disease progression, respectively. Using the 0·04 threshold to differentiate low from high COVID-19-associated risk would allow selecting patients with mild disease at presentation for earlier drug treatment, thereby decreasing the risk of worsening disease and death and reducing hospitalisation costs. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 23, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 23, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 23, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 23, 2022. ; https://doi.org/10.1101/2022.01.20.22269599 doi: medRxiv preprint COV50 as guide to earlier COVID-19 treatment -26- RAS blockers indicate blocker of the renin-angiotensin system, including angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers. Systolic and diastolic blood pressure and heart rate were missing in 2 initially recruited participants and 29 participants recruited later. The p value refers to the differences in the study participants' characteristics between initial recruitment (25 March 2020 -18 November 2020) and continued recruitment (30 April 2020 -14 April 2021). RAS=renin-angiotensin system. Hospital costs per care facility (median and 95% percentile interval) were extrapolated from the distribution of patients to be expected by Markov chain simulation reaching follow-up WHO scores of 3-4, 5, and 6-8 and the care facility corresponding with disease severity, i.e., regular, intermediate and intensive care for scores 3-4, 5, and 6-8, respectively. Given the simulated number of patients, hospitalisation costs were then computed based on the median number of hospital days per care facility, as observed in the CRIT-Cov-U cohort and a flat facility-specific costing rate harmonised across countries using the 2020 national gross domestic product with the costs in Germany as reference. Hospitalisation costs were standardised to 1000 patients in each risk stratum. Days refers to the median number of days (95% percentile interval) as observed in the CRIT-Cov-U cohort. M€ indicates million Euro.

.

It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in The base model included sex, age, body mass index and the presence of comorbidities: hypertension, heart failure, diabetes or cancer. In subsequent steps, the baseline WHO score was added and next COV50 as a continuously distributed variable (panels B and E) or as a categorised variable based on an optimised threshold of 0·47 for mortality (panel C) or 0·04 for a worsening WHO score (panel F).

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 23, 2022. ;

Heavily mutated omicron variant puts scientists on alert

Highly mutated SARS-CoV-2 Omicron variant sparks significant concern among global experts -What is known so far

A specific urinary peptidomic profile predicts outcome in SARS-CoV-2-infected patients

World Health Organization. Ordinal scale for clinical improvement. WHO R&D Blueprint Novel Coronavirus

Urinary proteomics associate with COVID-19 severity: pilot proof-of-principle data and design of multicentric diagnostic study

Markov chains as a predictive analytics technique using SAS/IML

COV50 as guide to earlier COVID-19 treatment -22

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein

Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial

Small molecule-mediated inhibition of myofibroblast transdifferentiation for the treatment of fibrosis

Cardiac microvascular endothelial cells in pressure overload-induced heart disease

Chronic kidney disease is a risk factor for severe COVID-19: a call to action by ERA-EDTA

CD99 and polymeric immunoglobulin receptor peptides deregulation in critical COVID-19: a potential link to molecular pathophysiology?

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial